Reverse phase protein array: validation of a novel proteomic technology and utility for analysis of primary leukemia specimens and hematopoietic stem cells - PubMed (original) (raw)
Comparative Study
Reverse phase protein array: validation of a novel proteomic technology and utility for analysis of primary leukemia specimens and hematopoietic stem cells
Raoul Tibes et al. Mol Cancer Ther. 2006 Oct.
Abstract
Proteomics has the potential to provide answers in cancer pathogenesis and to direct targeted therapy through the comprehensive analysis of protein expression levels and activation status. The realization of this potential requires the development of new, rapid, high-throughput technologies for performing protein arrays on patient samples, as well as novel analytic techniques to interpret them. Herein, we describe the validation and robustness of using reverse phase protein arrays (RPPA) for the analysis of primary acute myelogenous leukemia samples as well as leukemic and normal stem cells. In this report, we show that array printing, detection, amplification, and staining precision are very high, reproducible, and that they correlate with traditional Western blotting. Using replicates of the same sample on the same and/or separate arrays, or using separate protein samples prepared from the same starting sample, the intra- and interarray reproducibility was extremely high. No statistically significant difference in protein signal intensities could be detected within the array setups. The activation status (phosphorylation) was maintained in experiments testing delayed processing and preparation from multiple freeze-thawed samples. Differences in protein expression could reliably be detected in as few as three cell protein equivalents. RPPA prepared from rare populations of normal and leukemic stem cells were successfully done and showed differences from bulk populations of cells. Examples show how RPPAs are ideally suited for the large-scale analysis of target identification, validation, and drug discovery. In summary, RPPA is a highly reliable, reproducible, high-throughput system that allows for the rapid large-scale proteomic analysis of protein expression and phosphorylation state in primary acute myelogenous leukemia cells, cell lines, and in human stem cells.
Similar articles
- Reverse phase protein arrays in acute leukemia: investigative and methodological challenges.
Hoff FW, Horton TM, Kornblau SM. Hoff FW, et al. Expert Rev Proteomics. 2021 Dec;18(12):1087-1097. doi: 10.1080/14789450.2021.2020655. Epub 2021 Dec 29. Expert Rev Proteomics. 2021. PMID: 34965151 Free PMC article. Review. - Subtyping of breast cancer using reverse phase protein arrays.
Sonntag J, Schlüter K, Bernhardt S, Korf U. Sonntag J, et al. Expert Rev Proteomics. 2014 Dec;11(6):757-70. doi: 10.1586/14789450.2014.971113. Expert Rev Proteomics. 2014. PMID: 25400094 Review. - Evaluation of reverse phase protein array (RPPA)-based pathway-activation profiling in 84 non-small cell lung cancer (NSCLC) cell lines as platform for cancer proteomics and biomarker discovery.
Ummanni R, Mannsperger HA, Sonntag J, Oswald M, Sharma AK, König R, Korf U. Ummanni R, et al. Biochim Biophys Acta. 2014 May;1844(5):950-9. doi: 10.1016/j.bbapap.2013.11.017. Epub 2013 Dec 19. Biochim Biophys Acta. 2014. PMID: 24361481 - Clinical utility of reverse phase protein array for molecular classification of breast cancer.
Negm OH, Muftah AA, Aleskandarany MA, Hamed MR, Ahmad DA, Nolan CC, Diez-Rodriguez M, Tighe PJ, Ellis IO, Rakha EA, Green AR. Negm OH, et al. Breast Cancer Res Treat. 2016 Jan;155(1):25-35. doi: 10.1007/s10549-015-3654-2. Epub 2015 Dec 9. Breast Cancer Res Treat. 2016. PMID: 26661092 - MicroRNA-9 promotes proliferation of leukemia cells in adult CD34-positive acute myeloid leukemia with normal karyotype by downregulation of Hes1.
Tian C, You MJ, Yu Y, Zhu L, Zheng G, Zhang Y. Tian C, et al. Tumour Biol. 2016 Jun;37(6):7461-71. doi: 10.1007/s13277-015-4581-x. Epub 2015 Dec 17. Tumour Biol. 2016. PMID: 26678889
Cited by
- A protein expression atlas on tissue samples and cell lines from cancer patients provides insights into tumor heterogeneity and dependencies.
Li J, Liu W, Mojumdar K, Kim H, Zhou Z, Ju Z, Kumar SV, Ng PK, Chen H, Davies MA, Lu Y, Akbani R, Mills GB, Liang H. Li J, et al. Nat Cancer. 2024 Oct;5(10):1579-1595. doi: 10.1038/s43018-024-00817-x. Epub 2024 Sep 3. Nat Cancer. 2024. PMID: 39227745 - Epithelial to mesenchymal transition is associated with rapamycin resistance.
Holder AM, Akcakanat A, Adkins F, Evans K, Chen H, Wei C, Milton DR, Li Y, Do KA, Janku F, Meric-Bernstam F. Holder AM, et al. Oncotarget. 2015 Aug 14;6(23):19500-13. doi: 10.18632/oncotarget.3669. Oncotarget. 2015. PMID: 25944619 Free PMC article. - Protein and phosphoprotein levels in glioma and adenocarcinoma cell lines grown in normoxia and hypoxia in monolayer and three-dimensional cultures.
Levin VA, Panchabhai S, Shen L, Baggerly KA. Levin VA, et al. Proteome Sci. 2012 Jan 25;10(1):5. doi: 10.1186/1477-5956-10-5. Proteome Sci. 2012. PMID: 22276931 Free PMC article. - Huaier aqueous extract inhibits ovarian cancer cell motility via the AKT/GSK3β/β-catenin pathway.
Yan X, Lyu T, Jia N, Yu Y, Hua K, Feng W. Yan X, et al. PLoS One. 2013 May 8;8(5):e63731. doi: 10.1371/journal.pone.0063731. Print 2013. PLoS One. 2013. PMID: 23667667 Free PMC article. - Studying Cellular Signal Transduction with OMIC Technologies.
Landry BD, Clarke DC, Lee MJ. Landry BD, et al. J Mol Biol. 2015 Oct 23;427(21):3416-40. doi: 10.1016/j.jmb.2015.07.021. Epub 2015 Aug 3. J Mol Biol. 2015. PMID: 26244521 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical